[144] Labcorp Holdings Inc. SEC Filing

Rhea-AI Filing Summary

Labcorp Holdings Inc. insider notice reports a proposed sale of 5,643 common shares for an aggregate market value of $1,505,439.54, to be executed through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/11/2025. The shares were acquired on 03/30/2023 by restricted stock vesting as compensation. The filing also shows the seller previously sold 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65. The issuer's total outstanding common shares are reported as 83,100,000. By signing, the seller represents no undisclosed material adverse information and notes the compliance statements relevant to Rule 144 and Rule 10b5-1.

Insights

Securities Analyst

TL;DR: Routine insider notice to sell a small number of vested shares; unlikely to be material to valuation.

The filing shows an officer or insider proposing to sell 5,643 shares valued at $1.51M, with an earlier sale of 6,105 shares in the prior three months. Against 83.1M shares outstanding, these transactions represent a de minimis ownership change. The shares were received via restricted stock vesting, indicating compensation-related disposition rather than capital raising. From a market-impact perspective, the size and frequency suggest routine liquidity management rather than a material signal about firm fundamentals.

Corporate Governance Expert

TL;DR: Filing appears compliant with Rule 144 disclosure; no governance red flags evident from this notice alone.

The notice provides required broker details (Fidelity Brokerage Services), acquisition history, and a representation that no material nonpublic information is known. The presence of prior recent sales is disclosed, and the acquisition method (restricted stock vesting) is consistent with executive compensation practices. Absent additional context—such as large concentrated disposals, sudden executive departures, or conflicting disclosure—this Form 144 is a standard insider sale notice and does not in itself indicate governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	5643	1505439.54	83100000	08/11/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/30/2023	Restricted Stock Vesting	Issuer			5643	03/30/2023	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Adam H. Schechter 358 South Main Street Burlington NC 27215	Common	05/12/2025	6105	1518496.65

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

Who is the filer selling Labcorp (LH) shares in this Form 144?

The document lists Adam H. Schechter as a recent seller and the person for whose account shares are to be sold.

How many Labcorp (LH) shares are proposed for sale and what is their aggregate value?

The proposed sale is 5,643 common shares with an aggregate market value of $1,505,439.54.

When were the shares being sold originally acquired by the filer?

The shares were acquired on 03/30/2023 through restricted stock vesting as compensation.

Did the filer sell any Labcorp (LH) shares in the past three months?

Yes, the filing discloses a sale of 6,105 shares on 05/12/2025 for gross proceeds of $1,518,496.65.

Through which broker and exchange will the proposed sale occur?

The proposed sale is to be executed via Fidelity Brokerage Services LLC on the NYSE.

How large is the proposed sale relative to outstanding shares?

The issuer reports 83,100,000 shares outstanding; the proposed sale of 5,643 shares is a very small fraction of that total.